WO2011069913A1 - Method for screening active agents that stimulate the expression of cert to improve the skin's barrier function - Google Patents
Method for screening active agents that stimulate the expression of cert to improve the skin's barrier function Download PDFInfo
- Publication number
- WO2011069913A1 WO2011069913A1 PCT/EP2010/068849 EP2010068849W WO2011069913A1 WO 2011069913 A1 WO2011069913 A1 WO 2011069913A1 EP 2010068849 W EP2010068849 W EP 2010068849W WO 2011069913 A1 WO2011069913 A1 WO 2011069913A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- cert
- expression
- active agents
- selecting
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 44
- 230000014509 gene expression Effects 0.000 title claims abstract description 37
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000012216 screening Methods 0.000 title claims abstract description 15
- 230000008591 skin barrier function Effects 0.000 title description 8
- 101150050163 CERT1 gene Proteins 0.000 title 1
- 210000002510 keratinocyte Anatomy 0.000 claims abstract description 23
- 230000004888 barrier function Effects 0.000 claims abstract description 11
- 230000006735 deficit Effects 0.000 claims abstract description 8
- 230000001575 pathological effect Effects 0.000 claims abstract description 7
- 101710119334 Ceramide transfer protein Proteins 0.000 claims description 43
- 102100035437 Ceramide transfer protein Human genes 0.000 claims description 43
- 210000003491 skin Anatomy 0.000 claims description 43
- 239000000284 extract Substances 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 238000011002 quantification Methods 0.000 claims description 5
- 238000001262 western blot Methods 0.000 claims description 5
- 230000035515 penetration Effects 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 206010051246 Photodermatosis Diseases 0.000 claims description 2
- 230000000254 damaging effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000001590 oxidative effect Effects 0.000 claims description 2
- 230000008845 photoaging Effects 0.000 claims description 2
- 238000003757 reverse transcription PCR Methods 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 abstract description 15
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 abstract description 6
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 abstract description 6
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 abstract description 6
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 abstract description 6
- 108010078791 Carrier Proteins Proteins 0.000 abstract description 3
- 102000014914 Carrier Proteins Human genes 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 22
- 239000000523 sample Substances 0.000 description 15
- -1 polydimethylsiloxanes Polymers 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000002537 cosmetic Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 150000001783 ceramides Chemical class 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 7
- 238000010186 staining Methods 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 4
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- 230000037365 barrier function of the epidermis Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 229920001519 homopolymer Polymers 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000005575 Cellulases Human genes 0.000 description 2
- 108010084185 Cellulases Proteins 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004952 Polyamide Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 244000290333 Vanilla fragrans Species 0.000 description 2
- 235000009499 Vanilla fragrans Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 210000000736 corneocyte Anatomy 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical class NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
- 239000003495 polar organic solvent Substances 0.000 description 2
- 229920002647 polyamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- OIQXFRANQVWXJF-QBFSEMIESA-N (2z)-2-benzylidene-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical class CC1(C)C2CCC1(C)C(=O)\C2=C/C1=CC=CC=C1 OIQXFRANQVWXJF-QBFSEMIESA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical class N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- TYYHDKOVFSVWON-UHFFFAOYSA-N 2-butyl-2-methoxy-1,3-diphenylpropane-1,3-dione Chemical compound C=1C=CC=CC=1C(=O)C(OC)(CCCC)C(=O)C1=CC=CC=C1 TYYHDKOVFSVWON-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- DWYHDSLIWMUSOO-UHFFFAOYSA-N 2-phenyl-1h-benzimidazole Chemical class C1=CC=CC=C1C1=NC2=CC=CC=C2N1 DWYHDSLIWMUSOO-UHFFFAOYSA-N 0.000 description 1
- BVNWQSXXRMNYKH-UHFFFAOYSA-N 4-phenyl-2h-benzotriazole Chemical class C1=CC=CC=C1C1=CC=CC2=C1NN=N2 BVNWQSXXRMNYKH-UHFFFAOYSA-N 0.000 description 1
- XDGPRIQAERKLFM-UHFFFAOYSA-N 5-oxohept-6-ene-3-sulfonic acid Chemical compound CCC(S(O)(=O)=O)CC(=O)C=C XDGPRIQAERKLFM-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- OXJGJKIURHREKH-UHFFFAOYSA-O CC(=C)C(=O)OCCP(=O)=C(O)C[N+](C)(C)C Chemical compound CC(=C)C(=O)OCCP(=O)=C(O)C[N+](C)(C)C OXJGJKIURHREKH-UHFFFAOYSA-O 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 229920002907 Guar gum Chemical class 0.000 description 1
- 101000737563 Homo sapiens Ceramide transfer protein Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 241000219745 Lupinus Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241001599018 Melanogaster Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- YBGZDTIWKVFICR-JLHYYAGUSA-N Octyl 4-methoxycinnamic acid Chemical compound CCCCC(CC)COC(=O)\C=C\C1=CC=C(OC)C=C1 YBGZDTIWKVFICR-JLHYYAGUSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- 229920000289 Polyquaternium Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical class OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000589596 Thermus Species 0.000 description 1
- 241000589499 Thermus thermophilus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 241000219977 Vigna Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940051879 analgesics and antipyretics salicylic acid and derivative Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005193 avobenzone Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 150000008366 benzophenones Chemical class 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Chemical class NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000004061 bleaching Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical class C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 150000001851 cinnamic acid derivatives Chemical class 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000006003 cornification Effects 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Chemical class 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NZZIMKJIVMHWJC-UHFFFAOYSA-N dibenzoylmethane Chemical class C=1C=CC=CC=1C(=O)CC(=O)C1=CC=CC=C1 NZZIMKJIVMHWJC-UHFFFAOYSA-N 0.000 description 1
- OTKJDMGTUTTYMP-UHFFFAOYSA-N dihydrosphingosine Natural products CCCCCCCCCCCCCCCC(O)C(N)CO OTKJDMGTUTTYMP-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical class CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 239000000665 guar gum Chemical class 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000013178 mathematical model Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical class C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 description 1
- 229960001679 octinoxate Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000000485 pigmenting effect Effects 0.000 description 1
- 239000010773 plant oil Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002189 poly(glycerol 1-O-monomethacrylate) polymer Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229920002379 silicone rubber Polymers 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000008417 skin turnover Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- OTKJDMGTUTTYMP-ZWKOTPCHSA-N sphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@@H](N)CO OTKJDMGTUTTYMP-ZWKOTPCHSA-N 0.000 description 1
- WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000036572 transepidermal water loss Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 230000028973 vesicle-mediated transport Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000000230 xanthan gum Chemical class 0.000 description 1
- 229920001285 xanthan gum Chemical class 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/20—Dermatological disorders
Definitions
- the present invention relates to a method for screening an active agent intended for preventing or combating the cutaneous signs resulting from a non-pathological impairment of barrier function, comprising the selection of active agents that stimulate the expression of the ceramide transport protein CERT in cultured human keratinocytes .
- the skin consists mainly of three layers, namely, starting from the uppermost layer, the epidermis, the dermis and the hypodermis.
- the epidermis in particular consists of keratinocytes (predominantly), melanocytes (involved in pigmenting the skin) and Langerhans cells. Its function is to protect the body from the external environment and to ensure its integrity, and especially to halt the penetration of microorganisms or chemical substances, to prevent evaporation of the water contained in the skin and to constitute a barrier against external attack and especially against ultraviolet rays (UV) .
- UV ultraviolet rays
- keratinocytes undergo a process of proliferation and then of continuous directed maturation during which the keratinocytes located in the basal layer of the epidermis form, at the final stage of their differentiation, corneocytes, which are totally keratinized dead cells in the form of horny sheaths consisting of proteins and lipids such as epidermal ceramides.
- corneocytes which are totally keratinized dead cells in the form of horny sheaths consisting of proteins and lipids such as epidermal ceramides.
- intercorneocytic epidermal lipids are also formed and then organized in the form of bilayers (lamellae) in the stratum corneum, and they participate, with the abovementioned horny sheaths, in the barrier function of the epidermis.
- the lipid content of the stratum corneum consists of approximately 50% ceramides, 25% cholesterol, and 15% free fatty acids.
- Epidermal ceramides are synthesized by keratinocytes in a complex, multi-step cascade of reactions which begin in the endoplasmic reticulum (ER) . Ceramides are transported from the ER to the Golgi apparatus for further modification to sphingomyelin through either vesicular or non-vesicular transport. Non-vesicular transport is the major mechanism.
- Sphingomyelin is then transported to lamellar bodies and excreted from the keratinocytes to be further processed in the stratum corneum, during terminal differentiation, into some of the epidermal ceramides which are then incorporated into the lamellar membrane structures that subserve the permeability barrier to water loss (Y. Uchida et al . , Journal of Lipid Research, Vol. 41, 2071-2082, 2000).
- the barrier function of the epidermis may, however, be perturbed under certain climatic conditions (for example under the effect of cold and/or the wind) or under the effect of stress or fatigue, especially, thus promoting the penetration of allergens, irritants or microorganisms.
- These external factors may lead to drying of the skin (the skin loses its permeability, becomes dehydrated and its transepidermal water loss increases), and sensations of heating or redness, and also to impair the radiance of the complexion and the suppleness of the skin. Impairment of the skin barrier may also promote the appearance of microchapping or microcracks .
- a badly formed barrier resulting from impaired proliferation and differentiation processes, no longer protects the skin against UV radiation or any other type of external attack.
- the UV rays penetrating the skin may then produce free radicals which may have a detrimental effect on various targets, such as activate collagenases and elastases which are responsible for the degradation of collagen and elastin, respectively, and thus for a decrease in skin elasticity and firmness and the formation of wrinkles.
- compositions frequently incorporate active agents that act on one or more of the various biological targets involved either in skin turnover processes, in particular in keratinocyte differentiation, epidermal lipid synthesis and corneocyte cohesion, or in the endogenous synthesis of natural moisturizing factor (NMF) constituents of the skin, in particular in the synthesis of proteoglycans .
- active agents that act on one or more of the various biological targets involved either in skin turnover processes, in particular in keratinocyte differentiation, epidermal lipid synthesis and corneocyte cohesion, or in the endogenous synthesis of natural moisturizing factor (NMF) constituents of the skin, in particular in the synthesis of proteoglycans .
- NMF moisturizing factor
- Such active agents are especially a- and ⁇ -hydroxy acids, especially lactic acid, glycolic acid and salicylic acid; urea; and aminosulfonic compounds.
- the Applicant has, to its credit, shown, unexpectedly, that it is possible to act on a novel biological target, namely the ceramide transporter CERT, by stimulating the expression of this protein, in order to combat impairment of the barrier function.
- the Applicant has also, to its credit, developed an appropriate screening test for selecting active agents such as plant extracts acting on this target, thus making it possible to satisfy the abovementioned needs.
- CERT ceramide transport protein has elucidated a novel pathway to deliver ceramides synthesized in the ER to the Golgi for transformation into sphingomyelin (Hanada et al . Nature 426:803-809).
- the protein is identical in sequence, though not proposed function, to the Goodpasture antigen-binding protein (GPBP) splice variant GPBPA26.
- GPBP Goodpasture antigen-binding protein
- Mutation of CERT results in cells with significantly decreased sphingomyelin content.
- CERT mutation resulted in changes in cellular membrane fluidity which resulted in enhanced damage from oxidative stress and reduced organism lifespan (Rao et al. Proc. Nat. Acad. Sci .
- compositions comprising a drug which is a protein having the amino acid sequence of CERT.
- This drug may be used as an antitumor agent, an anti-inflammatory agent, an organoregenesis agent, an anti-infective agent, or a distribution promoting agent used for cosmetics. In the latter case, the drug may be applied onto skin so as to improve its water retention.
- One subject of the present invention is thus a method for screening active agents, which are able to prevent or combat the cutaneous signs resulting from non- pathological impairment of barrier function, comprising the following steps: a) treating a sample of cultured keratinocytes from a human donor with an active agent, such as a botanical extract ;
- step c) preferably comprises selecting the active agents that provide for at least a 1.7 fold increase in the gene expression level of CERT, compared to the untreated sample.
- step c) advantageously comprises selecting the active agents that provide for a CERT protein level which is at least 120% of that expressed by the untreated sample.
- any other means for quantifying the expression of CERT for instance by quantifying the production either of messenger RNA of CERT or of CERT protein, may be used without departing from this invention.
- the active agents that may be selected according to the invention are advantageously botanical extracts, i.e. active agents obtained by extraction, using any type of solvent, of any part of a plant such as bark, wood, roots, rhizomes, stalks, leaves, fruit or flowers, for example.
- the extraction may be performed on fresh or dried parts of the plant, optionally chopped or ground, in the usual manner.
- the extraction is generally performed by immersing or gently shaking in one or more polar or apolar solvents or a mixture thereof, at temperatures ranging, for example, from room temperature to 100°C and advantageously from 30 to 70°C, for a time of about 30 minutes to 12 hours and preferably from 1 to 8 hours.
- the resulting solution is then preferably filtered so as to remove the insoluble substances of the plant.
- the solvent is also, where appropriate, removed if it is a volatile solvent, for instance ethanol, methanol or isopropanol.
- the botanical extract may be prepared by extraction using a supercritical fluid such as carbon dioxide .
- it may be obtained by hydro-distillation, i.e. according to a method including a step for extracting vapour distillation residues, after elimination of the essential oils, by using a polar organic solvent having a polarity index greater than 3.5, possibly mixed with an apolar organic solvent having a polarity index less than 1.
- a polar organic solvent having a polarity index greater than 3.5 possibly mixed with an apolar organic solvent having a polarity index less than 1.
- All these extraction methods are common in the field of plant extracts and a person skilled in the art is capable of adjusting the reaction parameters thereof on the basis of his general knowledge.
- a botanical extract is obtained, which may then be subjected to a decolorizing step, especially using active charcoal in the presence of a solvent.
- the weight of active charcoal is preferably between 0.5% and 50% of the weight of the extract.
- One or more solvents chosen from water, C1-C4 alcohols such as methanol, ethanol or isopropanol, polar organic solvents such as propylene glycol or dipropylene glycol, or any other solvent that is common in the field, may especially be used.
- the volatile solvents may then be removed under reduced pressure.
- the skilled person will be able to prepare various botanical extracts, for example by varying the plants and solvents used. Alternatively, plant extracts that are commercially available may be used in this invention. These extracts should then be subjected to screening tests as described above and in the following examples, so as to determine whether any of these botanical extracts provides for an increase in the gene or protein expression level of CERT and may thus be selected according to this invention.
- the active agent selected according to the invention may be used for cosmetic purposes, to prevent or combat the cutaneous signs resulting from non-pathological impairment of the barrier function.
- the above-mentioned method may thus be used for selecting agents capable of protecting skin against signs of dryness such as: skin roughness, the loss of radiance of the complexion and/or the loss of suppleness of the skin ; for protecting skin from the external environment, especially from the damaging effects of UV rays or from the penetration of toxins, drugs, and chemical substances ; and for reducing oxidant load in the skin, when applied topically to human skin.
- the barrier integrity may especially be measured by corneometry, according to usual techniques that are well known to those skilled in the art.
- the screening method of this invention may be used for selecting agents capable of preventing skin photoaging, when applied topically to human skin.
- the active agent selected according to the invention, or the composition containing same are preferably applied to non-pathological dry skin and/or aged skin. They may advantageously be applied to the skin of the face, the neck and possibly the neckline or, as a variant, to any part of the body.
- the active agent is included in the cosmetic composition, for instance in a proportion of from 0.00001% to 10% by weight, preferably in a proportion of from 0.0001% to 5% by weight and more preferably in a proportion of from 0.001% to 1% by weight relative to the total weight of the composition.
- composition containing this active agent may be applied in the morning and/or in the evening, to the entire face, the neck and optionally the neckline or even the body.
- composition generally comprises, besides the active agent described previously, a physiologically acceptable and preferably cosmetically acceptable medium, i.e. a medium that is suitable for use in contact with human skin without any risk of toxicity, incompatibility, instability or allergic response and especially that does not cause any sensations of discomfort (redness, tautness, stinging, etc.) that are unacceptable to the user.
- a physiologically acceptable and preferably cosmetically acceptable medium i.e. a medium that is suitable for use in contact with human skin without any risk of toxicity, incompatibility, instability or allergic response and especially that does not cause any sensations of discomfort (redness, tautness, stinging, etc.) that are unacceptable to the user.
- This medium generally contains water and optionally other solvents such as ethanol.
- the composition containing the active agent selected according to the invention may be in any form that is suitable for topical application to the skin and in particular in the form of an oil-in-water , water-in-oil or multiple emulsion (W/O/W or 0/W/O), which may optionally be microemulsions or nanoemulsions , or in the form of an aqueous dispersion, a solution, an aqueous gel or an anhydrous composition. It is preferable for this composition to be in the form of an oil-in-water emulsion.
- This composition is preferably used as a care and/or cleansing product for facial and/or bodily skin and it may especially be in the form of a fluid, a gel or a mousse, conditioned, for example, in a pump-dispenser bottle, an aerosol or a tube, or in the form of cream conditioned, for example, in a jar. As a variant, it may be in the form of a makeup product and in particular a foundation or a loose or compact powder.
- oils which may be chosen especially from: linear or cyclic, volatile or non-volatile silicone oils, such as polydimethylsiloxanes (dimethicones ) , polyalkylcyclosiloxanes ( cyclomethicones ) and polyalkylphenylsiloxanes (phenyl dimethicones); synthetic oils such as fluoro oils, alkylbenzoates and branched hydrocarbons such as polyisobutylene ; plant oils and especially soybean oil or jojoba oil; and mineral oils such as liquid petroleum jelly;
- oils which may be chosen especially from: linear or cyclic, volatile or non-volatile silicone oils, such as polydimethylsiloxanes (dimethicones ) , polyalkylcyclosiloxanes ( cyclomethicones ) and polyalkylphenylsiloxanes (phenyl dimethicones); synthetic oils such as fluoro oils, alkylbenzoates and branched hydrocarbons
- waxes such as ozokerite, polyethylene wax, beeswax or carnauba wax;
- silicone elastomers obtained especially by reaction, in the presence of a catalyst, of a polysiloxane containing at least one reactive group (especially hydrogen or vinyl) and bearing at least one alkyl group (especially methyl) or phenyl, in a terminal and/or side position, with an organosilicone such as an organohydrogeno- polysiloxane;
- - surfactants preferably emulsifying surfactants, whether they are nonionic, anionic, cationic or amphoteric, and in particular fatty acid esters of polyols such as fatty acid esters of glycerol, fatty acid esters of sorbitan, fatty acid esters of polyethylene glycol and fatty acid esters of sucrose; fatty alkyl ethers of polyethylene glycol; alkylpolyglucosides ; polysiloxane-modified polyethers; betaine and derivatives thereof; polyquaterniums ; ethoxylated fatty alkyl sulfate salts; sulfosuccinates ; sarcosinates ; alkyl and dialkyl phosphates, and salts thereof; and fatty acid soaps;
- fatty acid esters of polyols such as fatty acid esters of glycerol, fatty acid esters of sorbitan, fatty acid esters of polyethylene glyco
- co-surfactants such as linear fatty alcohols and in particular cetyl alcohol and stearyl alcohol; thickeners and/or gelling agents, and in particular crosslinked or non-crosslinked, hydrophilic or amphiphilic homopolymers and copolymers, of acryloylmethylpropanesulfonic acid (AMPS) and/or of acrylamide and/or of acrylic acid and/or of acrylic acid salts or esters; xanthan gum or guar gum; cellulose derivatives; and silicone gums (dimethiconol ) ;
- AMPS acryloylmethylpropanesulfonic acid
- xanthan gum or guar gum cellulose derivatives
- silicone gums diimethiconol
- organic screening agents such as dibenzoylmethane derivatives (including butylmethoxydibenzoyl- methane) , cinnamic acid derivatives (including ethylhexyl methoxycinnamate ) , salicylates, para- aminobenzoic acids, ⁇ , ⁇ ' -diphenyl acrylates, benzophenones , benzylidenecamphor derivatives, phenylbenzimidazoles, triazines, phenyl- benzotriazoles and anthranilic derivatives;
- inorganic screening agents based on mineral oxides in the form of coated or uncoated pigments or nanopigments , and in particular based on titanium dioxide or zinc oxide;
- fillers and in particular powders with a soft- focus effect, which may be chosen especially from polyamides, silica, talc, mica and fibers (especially polyamide fiber or cellulose fiber) ; sequestrants such as EDTA salts;
- fragrances and mixtures thereof, without this list being limiting .
- composition containing the active agent selected according to the invention may also provide additional benefits, including calmative or anti-inflammatory activity, bleaching or depigmenting activity, anti- aging activity and/or cleansing activity.
- This composition may also comprise active agents other than those that stimulate the expression of CERT, and in particular at least one active agent chosen from: keratolytic agents and in particular o-hydroxy acids such as glycolic acid, lactic acid and citric acid, and esters or salts thereof; ⁇ -hydroxy acids such as salicylic acid and derivatives thereof; agents for increasing keratinocyte differentiation and/or cornification, either directly or indirectly by stimulating, for example, the production of ⁇ -endorphins , such as extracts of Thermus thermophilus or extracts of bean husks of Theobroma cacao, water- soluble extracts of corn, peptide extracts of Voandzeia substerranea and niacinamide; epidermal lipids and agents for increasing the synthesis of epidermal lipids, either directly or by stimulating certain
- Example 1 Test for screening active agents by Western blotting
- Keratinocytes derived from neonatal foreskins are inoculated in 6-well plates and cultured in keratinocyte growth culture medium (Epilife, Invitrogen, CA, USA), i.e. a modified culture medium supplemented with Epilife defined growth supplement (EDGS) .
- Epilife, Invitrogen, CA, USA i.e. a modified culture medium supplemented with Epilife defined growth supplement (EDGS) .
- WB Western blotting
- Cells incubated as described above are lysed and the extracted proteins are separated by SDS-PAGE.
- proteins are transferred to a PVDF membrane which is probed with anti-CERT antibody (Bethyl Laboratories, TX, USA) .
- the results are normalized to the amount of total protein in each sample.
- the results are expressed in terms of the percent (%) increase or decrease of expression of the target protein CERT in the treated sample versus the untreated control.
- the total protein content is quantified using the MicroBCA kit (Thermo Scientific, IL, USA) .
- vanilla Planifolia extracts make it possible to stimulate the expression of CERT protein in normal human keratinocytes and may thus be used to improve or restore skin barrier function .
- Example 2 Test for screening active agents by RT-PCR
- Protocol The effect of two active agents on the expression of the mRNA of CERT was evaluated in keratinocytes .
- Keratinocytes derived from neonatal foreskins are inoculated in 6-well plates and cultured in keratinocyte growth culture medium (Epilife, Invitrogen) , i.e. a modified culture medium supplemented with EDGS .
- the real-time PCR measurement is performed using the iCYCLER IQ machine (Bio-Rad, CA, USA) with Taqman probes.
- the PCR primers are obtained from Applied Biosystems (Applied Biosystems, CA, USA) .
- the cDNA is amplified using a standardized program. Each sample is charged with Taqman master-mix, Taqman primers, and water. The final amount of cDNA per reaction corresponds to 75 ng of total RNA used for the reverse transcription.
- the results are normalized relative to the expression of a housekeeping gene in these samples and corrected as regards the differences in efficacy of PCR.
- the housekeeping gene used here was RPLPO .
- the relative quantification of the expression of the target gene is performed using the Pfaffl mathematical model (Pfaffl, MW, Nucleic Acids Res. 29(9), p. E45, 2001).
- the results are expressed in terms of the number of times of increase or of decrease of expression of the target gene CERT in the treated sample.
- the variation in expression of the CERT protein was evaluated by immunohistochemistry (IHC), on paraffin- embedded skin samples from donors of various age groups (Cybrdi, MD, USA and Tissue Array Networks, MD, USA) . Staining was performed on 6 pm sections from donors in 4 age groups (20-30 weeks old, 28-35 years old, 39-49, and 50-69 years old) , with anti-CERT antibodies (Bethyl Laboratories, TX, USA) and secondary antibodies (Lab Vision, CA, USA) . The staining was visualized using the AEC system (Lab Vision) .
- Example 4 Cosmetic composition The following composition may be prepared in a manner that is conventional for those skilled in the art. The amounts indicated below are expressed as weight percentages. The ingredients in upper case are identified in accordance with the INCI name.
- Aqueous-phase gelling agents 5.50
- This composition in the form of an oil-in-water emulsion, may be applied daily, morning and/or evening, to facial skin to moisturize it and make it supple, smooth and luminous .
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The present invention relates to a method for screening an active agent intended for preventing or combating the cutaneous signs resulting from a non- pathological impairment of barrier function, comprising the selection of active agents that stimulate the expression of the ceramide transport protein CERT in cultured human keratinocytes.
Description
Method for screening active agents that stimulate the expression of CERT to improve the skin's barrier function The present invention relates to a method for screening an active agent intended for preventing or combating the cutaneous signs resulting from a non-pathological impairment of barrier function, comprising the selection of active agents that stimulate the expression of the ceramide transport protein CERT in cultured human keratinocytes .
The skin consists mainly of three layers, namely, starting from the uppermost layer, the epidermis, the dermis and the hypodermis.
The epidermis in particular consists of keratinocytes (predominantly), melanocytes (involved in pigmenting the skin) and Langerhans cells. Its function is to protect the body from the external environment and to ensure its integrity, and especially to halt the penetration of microorganisms or chemical substances, to prevent evaporation of the water contained in the skin and to constitute a barrier against external attack and especially against ultraviolet rays (UV) .
To do this, keratinocytes undergo a process of proliferation and then of continuous directed maturation during which the keratinocytes located in the basal layer of the epidermis form, at the final stage of their differentiation, corneocytes, which are totally keratinized dead cells in the form of horny sheaths consisting of proteins and lipids such as epidermal ceramides. During this differentiation process, intercorneocytic epidermal lipids are also formed and then organized in the form of bilayers (lamellae) in the stratum corneum, and they participate, with the abovementioned horny sheaths, in the barrier function of the epidermis.
The lipid content of the stratum corneum consists of approximately 50% ceramides, 25% cholesterol, and 15% free fatty acids. Epidermal ceramides are synthesized by keratinocytes in a complex, multi-step cascade of reactions which begin in the endoplasmic reticulum (ER) . Ceramides are transported from the ER to the Golgi apparatus for further modification to sphingomyelin through either vesicular or non-vesicular transport. Non-vesicular transport is the major mechanism. Sphingomyelin is then transported to lamellar bodies and excreted from the keratinocytes to be further processed in the stratum corneum, during terminal differentiation, into some of the epidermal ceramides which are then incorporated into the lamellar membrane structures that subserve the permeability barrier to water loss (Y. Uchida et al . , Journal of Lipid Research, Vol. 41, 2071-2082, 2000).
The barrier function of the epidermis may, however, be perturbed under certain climatic conditions (for example under the effect of cold and/or the wind) or under the effect of stress or fatigue, especially, thus promoting the penetration of allergens, irritants or microorganisms. These external factors may lead to drying of the skin (the skin loses its permeability, becomes dehydrated and its transepidermal water loss increases), and sensations of heating or redness, and also to impair the radiance of the complexion and the suppleness of the skin. Impairment of the skin barrier may also promote the appearance of microchapping or microcracks .
Furthermore, a badly formed barrier, resulting from impaired proliferation and differentiation processes, no longer protects the skin against UV radiation or any other type of external attack. The UV rays penetrating the skin may then produce free radicals which may have a detrimental effect on various targets, such as
activate collagenases and elastases which are responsible for the degradation of collagen and elastin, respectively, and thus for a decrease in skin elasticity and firmness and the formation of wrinkles.
To prevent or correct this phenomenon, it is known practice to apply to the skin cosmetic compositions containing hygroscopic agents, such as sugars or polyols, which are intended to take up the water present in the skin and thus to impede its evaporation. Use has also conventionally been made of fatty substances that allow an occlusive film to be formed on the skin, which contributes towards impeding the evaporation of water. Moreover, these compositions frequently incorporate active agents that act on one or more of the various biological targets involved either in skin turnover processes, in particular in keratinocyte differentiation, epidermal lipid synthesis and corneocyte cohesion, or in the endogenous synthesis of natural moisturizing factor (NMF) constituents of the skin, in particular in the synthesis of proteoglycans .
Examples of such active agents are especially a- and β-hydroxy acids, especially lactic acid, glycolic acid and salicylic acid; urea; and aminosulfonic compounds.
It is also known practice, to improve skin barrier function by applying onto skin an intermediate of the synthetic pathways, or precursor, for ceramides chosen from the sphinganine and sphingosine bases, such as 6- hydroxy-4-sphingenine (FR-2 , 811 , 556 ) .
Similarly, it has also been proposed to act on some biological targets which increase the ceramide content of skin lipids, in order to improve skin barrier function. Among these targets, mention can be made of β-glucosidases , which have been shown to be stimulated
by carbohydrates such as O-octanoyl-6 ' -maltose (WO 02/38110) .
However, there always remains the need to propose novel cosmetic active agents for reinforcing the skin's barrier function to prevent and/or reduce the sensations of cutaneous discomfort, stinging, tautness, itching, sensations of heating or redness and/or the appearance of microchapping or microcracking and/or the loss of radiance of the complexion or dull complexion and/or the loss of suppleness of the skin and/or to improve the protection of the epidermis against UV.
In addition, given the ever-increasing search by consumers for natural products containing the fewest possible synthetic ingredients, and the increasingly burdensome regulatory constraints on compounds derived from the chemical industry, it would be desirable for these cosmetic active agents to be of plant origin.
Now, the Applicant has, to its credit, shown, unexpectedly, that it is possible to act on a novel biological target, namely the ceramide transporter CERT, by stimulating the expression of this protein, in order to combat impairment of the barrier function. The Applicant has also, to its credit, developed an appropriate screening test for selecting active agents such as plant extracts acting on this target, thus making it possible to satisfy the abovementioned needs.
The recently discovered CERT ceramide transport protein has elucidated a novel pathway to deliver ceramides synthesized in the ER to the Golgi for transformation into sphingomyelin (Hanada et al . Nature 426:803-809). The protein is identical in sequence, though not proposed function, to the Goodpasture antigen-binding protein (GPBP) splice variant GPBPA26. Mutation of CERT results in cells with significantly decreased sphingomyelin content. In D. melanogaster cells, CERT
mutation resulted in changes in cellular membrane fluidity which resulted in enhanced damage from oxidative stress and reduced organism lifespan (Rao et al. Proc. Nat. Acad. Sci . USA 104:11364-11369). Exposure of cultured keratinocytes or ex vivo murine skin to UVB resulted in the inability of CERT to efficiently transport ceramide and further resulted in increased cell death (Charruyer et al . J. Biol. Chem. 283 : 16682-16692) .
In order to improve ceramide transport, it has been proposed in EP 1 652 530 to administer compositions comprising a drug which is a protein having the amino acid sequence of CERT. This drug may be used as an antitumor agent, an anti-inflammatory agent, an organoregenesis agent, an anti-infective agent, or a distribution promoting agent used for cosmetics. In the latter case, the drug may be applied onto skin so as to improve its water retention.
To the Applicant's knowledge, however, cosmetic active agents that stimulate the expression of CERT have never been disclosed. Moreover, it has never been suggested that CERT expression could be stimulated in keratinocytes with a view to improving epidermal barrier function.
Furthermore, the Applicant has shown that the expression of CERT decreased with age. Thus, compounds that stimulate the expression of CERT could also be useful to prevent and/or treat the signs of skin ageing . One subject of the present invention is thus a method for screening active agents, which are able to prevent or combat the cutaneous signs resulting from non- pathological impairment of barrier function, comprising the following steps:
a) treating a sample of cultured keratinocytes from a human donor with an active agent, such as a botanical extract ;
b) quantifying the expression of CERT in said treated sample, relative to the same cell sample which has not been treated;
c) selecting the active agents that provide for an increase in the expression of CERT relative to the untreated sample.
In this method, the quantification of the expression of CERT may be performed by real-time RT-PCR on cultured keratinocytes . In this situation, step c) preferably comprises selecting the active agents that provide for at least a 1.7 fold increase in the gene expression level of CERT, compared to the untreated sample.
Alternatively, the quantification of the expression of CERT may be performed by Western blotting on cultured keratinocytes . In such a case, step c) advantageously comprises selecting the active agents that provide for a CERT protein level which is at least 120% of that expressed by the untreated sample. However, any other means for quantifying the expression of CERT, for instance by quantifying the production either of messenger RNA of CERT or of CERT protein, may be used without departing from this invention. The active agents that may be selected according to the invention are advantageously botanical extracts, i.e. active agents obtained by extraction, using any type of solvent, of any part of a plant such as bark, wood, roots, rhizomes, stalks, leaves, fruit or flowers, for example.
In general, the extraction may be performed on fresh or dried parts of the plant, optionally chopped or ground, in the usual manner. The extraction is generally
performed by immersing or gently shaking in one or more polar or apolar solvents or a mixture thereof, at temperatures ranging, for example, from room temperature to 100°C and advantageously from 30 to 70°C, for a time of about 30 minutes to 12 hours and preferably from 1 to 8 hours. The resulting solution is then preferably filtered so as to remove the insoluble substances of the plant. The solvent is also, where appropriate, removed if it is a volatile solvent, for instance ethanol, methanol or isopropanol.
Alternatively, the botanical extract may be prepared by extraction using a supercritical fluid such as carbon dioxide .
According to still another embodiment, it may be obtained by hydro-distillation, i.e. according to a method including a step for extracting vapour distillation residues, after elimination of the essential oils, by using a polar organic solvent having a polarity index greater than 3.5, possibly mixed with an apolar organic solvent having a polarity index less than 1. All these extraction methods are common in the field of plant extracts and a person skilled in the art is capable of adjusting the reaction parameters thereof on the basis of his general knowledge. After this extraction step, a botanical extract is obtained, which may then be subjected to a decolorizing step, especially using active charcoal in the presence of a solvent. The weight of active charcoal is preferably between 0.5% and 50% of the weight of the extract. One or more solvents chosen from water, C1-C4 alcohols such as methanol, ethanol or isopropanol, polar organic solvents such as propylene glycol or dipropylene glycol, or any other solvent that is common
in the field, may especially be used. The volatile solvents may then be removed under reduced pressure.
The skilled person will be able to prepare various botanical extracts, for example by varying the plants and solvents used. Alternatively, plant extracts that are commercially available may be used in this invention. These extracts should then be subjected to screening tests as described above and in the following examples, so as to determine whether any of these botanical extracts provides for an increase in the gene or protein expression level of CERT and may thus be selected according to this invention. When it passes the above screening test(s), the active agent selected according to the invention may be used for cosmetic purposes, to prevent or combat the cutaneous signs resulting from non-pathological impairment of the barrier function. The above-mentioned method may thus be used for selecting agents capable of protecting skin against signs of dryness such as: skin roughness, the loss of radiance of the complexion and/or the loss of suppleness of the skin ; for protecting skin from the external environment, especially from the damaging effects of UV rays or from the penetration of toxins, drugs, and chemical substances ; and for reducing oxidant load in the skin, when applied topically to human skin. The barrier integrity may especially be measured by corneometry, according to usual techniques that are well known to those skilled in the art.
As a variant, the screening method of this invention may be used for selecting agents capable of preventing skin photoaging, when applied topically to human skin.
The active agent selected according to the invention, or the composition containing same, are preferably
applied to non-pathological dry skin and/or aged skin. They may advantageously be applied to the skin of the face, the neck and possibly the neckline or, as a variant, to any part of the body.
In this regard, the active agent is included in the cosmetic composition, for instance in a proportion of from 0.00001% to 10% by weight, preferably in a proportion of from 0.0001% to 5% by weight and more preferably in a proportion of from 0.001% to 1% by weight relative to the total weight of the composition.
The composition containing this active agent may be applied in the morning and/or in the evening, to the entire face, the neck and optionally the neckline or even the body.
This composition generally comprises, besides the active agent described previously, a physiologically acceptable and preferably cosmetically acceptable medium, i.e. a medium that is suitable for use in contact with human skin without any risk of toxicity, incompatibility, instability or allergic response and especially that does not cause any sensations of discomfort (redness, tautness, stinging, etc.) that are unacceptable to the user.
This medium generally contains water and optionally other solvents such as ethanol. The composition containing the active agent selected according to the invention may be in any form that is suitable for topical application to the skin and in particular in the form of an oil-in-water , water-in-oil or multiple emulsion (W/O/W or 0/W/O), which may optionally be microemulsions or nanoemulsions , or in the form of an aqueous dispersion, a solution, an aqueous gel or an anhydrous composition. It is
preferable for this composition to be in the form of an oil-in-water emulsion.
This composition is preferably used as a care and/or cleansing product for facial and/or bodily skin and it may especially be in the form of a fluid, a gel or a mousse, conditioned, for example, in a pump-dispenser bottle, an aerosol or a tube, or in the form of cream conditioned, for example, in a jar. As a variant, it may be in the form of a makeup product and in particular a foundation or a loose or compact powder.
It may contain various adjuvants, such as at least one compound chosen from: oils, which may be chosen especially from: linear or cyclic, volatile or non-volatile silicone oils, such as polydimethylsiloxanes (dimethicones ) , polyalkylcyclosiloxanes ( cyclomethicones ) and polyalkylphenylsiloxanes (phenyl dimethicones); synthetic oils such as fluoro oils, alkylbenzoates and branched hydrocarbons such as polyisobutylene ; plant oils and especially soybean oil or jojoba oil; and mineral oils such as liquid petroleum jelly;
- waxes such as ozokerite, polyethylene wax, beeswax or carnauba wax;
silicone elastomers obtained especially by reaction, in the presence of a catalyst, of a polysiloxane containing at least one reactive group (especially hydrogen or vinyl) and bearing at least one alkyl group (especially methyl) or phenyl, in a terminal and/or side position, with an organosilicone such as an organohydrogeno- polysiloxane;
- surfactants, preferably emulsifying surfactants, whether they are nonionic, anionic, cationic or amphoteric, and in particular fatty acid esters of polyols such as fatty acid esters of glycerol,
fatty acid esters of sorbitan, fatty acid esters of polyethylene glycol and fatty acid esters of sucrose; fatty alkyl ethers of polyethylene glycol; alkylpolyglucosides ; polysiloxane-modified polyethers; betaine and derivatives thereof; polyquaterniums ; ethoxylated fatty alkyl sulfate salts; sulfosuccinates ; sarcosinates ; alkyl and dialkyl phosphates, and salts thereof; and fatty acid soaps;
co-surfactants such as linear fatty alcohols and in particular cetyl alcohol and stearyl alcohol; thickeners and/or gelling agents, and in particular crosslinked or non-crosslinked, hydrophilic or amphiphilic homopolymers and copolymers, of acryloylmethylpropanesulfonic acid (AMPS) and/or of acrylamide and/or of acrylic acid and/or of acrylic acid salts or esters; xanthan gum or guar gum; cellulose derivatives; and silicone gums (dimethiconol ) ;
organic screening agents, such as dibenzoylmethane derivatives (including butylmethoxydibenzoyl- methane) , cinnamic acid derivatives (including ethylhexyl methoxycinnamate ) , salicylates, para- aminobenzoic acids, β , β ' -diphenyl acrylates, benzophenones , benzylidenecamphor derivatives, phenylbenzimidazoles, triazines, phenyl- benzotriazoles and anthranilic derivatives;
inorganic screening agents, based on mineral oxides in the form of coated or uncoated pigments or nanopigments , and in particular based on titanium dioxide or zinc oxide;
dyes ;
preserving agents;
fillers, and in particular powders with a soft- focus effect, which may be chosen especially from polyamides, silica, talc, mica and fibers (especially polyamide fiber or cellulose fiber) ; sequestrants such as EDTA salts;
fragrances ;
and mixtures thereof, without this list being limiting .
Examples of such adjuvants are especially mentioned in the CTFA dictionary (International Cosmetic Ingredient Dictionary and Handbook published by The Cosmetic, Toiletry and Fragrance Association, 11th edition, 2006), which describes a wide variety, without limitation, of cosmetic and pharmaceutical ingredients usually used in the skincare industry, that are suitable for use as additional ingredients in the compositions according to the present invention.
The composition containing the active agent selected according to the invention may also provide additional benefits, including calmative or anti-inflammatory activity, bleaching or depigmenting activity, anti- aging activity and/or cleansing activity. This composition may also comprise active agents other than those that stimulate the expression of CERT, and in particular at least one active agent chosen from: keratolytic agents and in particular o-hydroxy acids such as glycolic acid, lactic acid and citric acid, and esters or salts thereof; β-hydroxy acids such as salicylic acid and derivatives thereof; agents for increasing keratinocyte differentiation and/or cornification, either directly or indirectly by stimulating, for example, the production of β-endorphins , such as extracts of Thermus thermophilus or extracts of bean husks of Theobroma cacao, water- soluble extracts of corn, peptide extracts of Voandzeia substerranea and niacinamide; epidermal lipids and agents for increasing the synthesis of epidermal lipids, either directly or by stimulating certain β-glucosidases that modulate the deglycosylation of lipid precursors such as glucosyl ceramide to ceramides, such as phospholipids, ceramides, lupin protein hydrolyzates and dihydro asmonic acid
derivatives; humectants, such as polyols and in particular glycerol, glycosaminoglycans such as hyaluronic acid, sugars and alkyl esters thereof, amino acids such as glycine, arginine, histidine, alanine, threonine, lysine, glutamic acid, taurine, proline, serine and derivatives thereof, pyrrolidonecarboxylic acid (PCA) and salts thereof, urea and derivatives thereof, ectoin, glucosamine, creatine, choline, betaine, mineral salts such as chlorine, sodium, potassium, calcium, magnesium, zinc, manganese or phosphate salts and humectant synthetic polymers such as methacryloyloxyethylphosphorylcholine homopolymers and copolymers, and glyceryl (meth) acrylate homopolymers and copolymers; antioxidants and/or free- radical scavengers and/or anti-pollution agents, such as tocopherol and esters thereof, ascorbic acid and the alkyl and phosphoryl esters thereof and certain extracts of plants or algae and in particular of Thermus thermophilics ; and mixtures thereof, without this list being limiting.
The combination of active agents that stimulate the expression of CERT with one or more of the agents described above makes it possible advantageously to combine in the same formula the effects of these two types of active agent and thus to obtain maximum and long-lasting protection of the skin.
The invention will now be illustrated by the non- limiting examples that follow.
EXAMPLES
Example 1 : Test for screening active agents by Western blotting
Protocol :
A Vanilla plan!folia extract was prepared as described in Example 1 of WO 2007/034042.
The effect of a botanical extract on the expression of CERT protein is evaluated on keratinocytes .
Keratinocytes derived from neonatal foreskins (Cascade Biologics/Invitrogen, Portland, OR, USA) are inoculated in 6-well plates and cultured in keratinocyte growth culture medium (Epilife, Invitrogen, CA, USA), i.e. a modified culture medium supplemented with Epilife defined growth supplement (EDGS) .
After culturing for 24 hours in an incubator at 37°C, the almost confluent cells are washed with PBS buffer (Invitrogen) and incubated with specific basic medium (Epilife, Invitrogen) containing the extract to be tested, for 24 hours and in triplicate, at increasing concentrations. Cytotoxicity of the extract is determined prior to determining its activity.
To quantify the expression of CERT protein in a treated sample relative to an untreated sample, Western blotting (WB) is used. Cells incubated as described above are lysed and the extracted proteins are separated by SDS-PAGE. Following electrophoresis, proteins are transferred to a PVDF membrane which is probed with anti-CERT antibody (Bethyl Laboratories, TX, USA) . The results are normalized to the amount of total protein in each sample. The results are expressed in terms of the percent (%) increase or decrease of expression of the target protein CERT in the treated sample versus the untreated control. The total protein content is quantified using the MicroBCA kit (Thermo Scientific, IL, USA) .
The positive results are confirmed using cells from at least two different donors.
Results : The results are given in Table 1 below:
Table 1
It emerges from this test that Vanilla Planifolia extracts make it possible to stimulate the expression of CERT protein in normal human keratinocytes and may thus be used to improve or restore skin barrier function .
Example 2 : Test for screening active agents by RT-PCR
Protocol : The effect of two active agents on the expression of the mRNA of CERT was evaluated in keratinocytes .
Keratinocytes derived from neonatal foreskins (Cascade Biologics/Invitrogen, Portland, OR, USA) are inoculated in 6-well plates and cultured in keratinocyte growth culture medium (Epilife, Invitrogen) , i.e. a modified culture medium supplemented with EDGS .
After culturing for 24 hours in an incubator at 37°C, the 70%-80% confluent cells are washed with PBS buffer (Invitrogen) and incubated with basic medium (Epilife, Invitrogen) containing the active agent to be tested,
for 24 hours and in triplicate, at increasing concentrations. After studying the cytotoxicity of the active agent, its activity is evaluated. To quantify the expression of CERT messenger RNA in a treated sample relative to an untreated sample, first the RNA is isolated using the RNeasy reagent kit (Qiagen, CA, USA) and then quantified using the Quantit kit (Invitrogen) . Reverse transcription is performed using the gene Amp RNA PCR kit (Applied Biosystems) according to the manufacturer's recommendations.
The real-time PCR measurement is performed using the iCYCLER IQ machine (Bio-Rad, CA, USA) with Taqman probes. The PCR primers are obtained from Applied Biosystems (Applied Biosystems, CA, USA) . In all the tests, the cDNA is amplified using a standardized program. Each sample is charged with Taqman master-mix, Taqman primers, and water. The final amount of cDNA per reaction corresponds to 75 ng of total RNA used for the reverse transcription.
The results are normalized relative to the expression of a housekeeping gene in these samples and corrected as regards the differences in efficacy of PCR. The housekeeping gene used here was RPLPO . The relative quantification of the expression of the target gene is performed using the Pfaffl mathematical model (Pfaffl, MW, Nucleic Acids Res. 29(9), p. E45, 2001). The results are expressed in terms of the number of times of increase or of decrease of expression of the target gene CERT in the treated sample.
Results :
The results are given in Table 2 below:
Table 2
It emerges from this test that the active agents tested make it possible to stimulate the expression of CERT protein in normal human keratinocytes and may thus be used to improve or restore skin barrier function.
Example 3 : Assessment of the expression of CERT with age
Protocol :
The variation in expression of the CERT protein was evaluated by immunohistochemistry (IHC), on paraffin- embedded skin samples from donors of various age groups (Cybrdi, MD, USA and Tissue Array Networks, MD, USA) . Staining was performed on 6 pm sections from donors in 4 age groups (20-30 weeks old, 28-35 years old, 39-49, and 50-69 years old) , with anti-CERT antibodies (Bethyl Laboratories, TX, USA) and secondary antibodies (Lab Vision, CA, USA) . The staining was visualized using the AEC system (Lab Vision) . Staining was assessed on 2-6 images each from 3-6 donors in each age group by doing a blind visual assessment of the intensity and extent of staining using a scale from 1 to 5 (1 = least intense, 5 = most intense) . Mean values of ratings were compaired for significance using the unpaired t-test.
Results :
Evaluation of CERT staining in young adult skin (28-35 yrs old) showed intense cytoplasmic staining in the epidermis which translated to a rating of 4.63 (±0.5) (Figure 1, dark grey bar) . The intensity of staining
then visibly decreased in sections of elder donor skin (39-49) and especially at 50-69 years of age, where staining intensity was rated 3.06 (±0.66). This demonstrates that expression of CERT protein is significantly diminished with increasing age (P < 0.0001) .
Example 4 : Cosmetic composition The following composition may be prepared in a manner that is conventional for those skilled in the art. The amounts indicated below are expressed as weight percentages. The ingredients in upper case are identified in accordance with the INCI name.
Tetrasodium EDTA 0.05
POLYGLYCERYL METHACRYLATE &
PROPYLENE GLYCOL (1) 5.00
Glycerol 6.00
Aqueous-phase gelling agents 5.50
Nonionic emulsifiers 4.00
Cetearyl alcohol 2.00
Emollients 17.00
Tocopheryl acetate 0.50
Preserving agents 2.20
Botanical extract12' 0.05
Sodium hyaluronate 5.00
Fragrance qs
Dyes qs
Water 100.00
LUBRAJEL MS® from Guardian Laboratories
obtained by screening various plant extracts on the test disclosed in Example 1 or 2
This composition, in the form of an oil-in-water emulsion, may be applied daily, morning and/or evening, to facial skin to moisturize it and make it supple, smooth and luminous .
Claims
1. A method for screening active agents, which are able to prevent or combat the cutaneous signs resulting from non-pathological impairment of barrier function, comprising the following steps:
a) treating a sample of cultured keratinocytes from a human donor with an active agent, such as a botanical extract ;
b) quantifying the expression of CERT in said treated sample, relative to the same cell sample which has not been treated;
c) selecting the active agents that provide for an increase in the expression of CERT relative to the untreated sample.
2. The method according to claim 1, characterized in that quantification of the expression of CERT is performed by RT-PCR.
3. The method according to claim 2, characterized in that step c) comprises selecting the active agents that provide for at least a 1.7 fold increase in the gene expression level of CERT, compared to an untreated sample where expression is at 1.
4. The method according to claim 1, characterized in that the quantification of the expression of CERT is performed by Western blotting.
5. The method according to claim 4, characterized in that step c) comprises selecting the active agents that provide for a CERT protein level, which is at least 120% of that expressed by the untreated sample.
6. Use of the method according to any of claims 1 to 5 for selecting active agents capable of preventing or combating the cutaneous signs resulting from non- pathological impairment of barrier function when applied topically to human skin.
7. Use of the method according to any of claims 1 to 5 for selecting active agents capable of protecting skin from signs of drying out, protecting skin from the external environment, especially from the damaging effects of UV rays or from the penetration of toxins, drugs, and chemical substances, and reducing oxidant load in the skin, when applied topically to human skin.
8. Use according to claim 7, characterized in that the said signs are chosen from: skin roughness, the loss of radiance of the complexion and/or the loss of suppleness of the skin.
9. Use of the method according to any one of claims 1 to 5, for selecting active agents capable of preventing skin photoaging when applied topically to human skin.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012542471A JP5847090B2 (en) | 2009-12-07 | 2010-12-03 | Method for screening active agents that stimulate the expression of CERT to improve the barrier function of the skin |
EP10787115.4A EP2510112B1 (en) | 2009-12-07 | 2010-12-03 | Method for screening active agents that stimulate the expression of cert to improve the skin's barrier function |
ES10787115.4T ES2526540T3 (en) | 2009-12-07 | 2010-12-03 | Method to select active agents that stimulate CERT expression to improve skin barrier functions |
US13/514,412 US9228999B2 (en) | 2009-12-07 | 2010-12-03 | Method for screening active agents that stimulate the expression of CERT to improve the skin's barrier function |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26715009P | 2009-12-07 | 2009-12-07 | |
US26715209P | 2009-12-07 | 2009-12-07 | |
US61/267,152 | 2009-12-07 | ||
US61/267,150 | 2009-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011069913A1 true WO2011069913A1 (en) | 2011-06-16 |
Family
ID=43533139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2010/068849 WO2011069913A1 (en) | 2009-12-07 | 2010-12-03 | Method for screening active agents that stimulate the expression of cert to improve the skin's barrier function |
Country Status (5)
Country | Link |
---|---|
US (1) | US9228999B2 (en) |
EP (1) | EP2510112B1 (en) |
JP (1) | JP5847090B2 (en) |
ES (1) | ES2526540T3 (en) |
WO (1) | WO2011069913A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012156420A1 (en) * | 2011-05-17 | 2012-11-22 | Chanel Parfums Beaute | Large, hs6st2 or st8sia1 activators for preventing and/or attenuating skin ageing and/or hydrating skin |
WO2014009566A1 (en) * | 2012-07-13 | 2014-01-16 | Laboratoires Expanscience | Method for identifying molecular markers of children's skin |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2811556A1 (en) | 2000-07-11 | 2002-01-18 | Oreal | COMPOSITION COMPRISING A PRECURSOR OF CERAMIDES, USE TO ENHANCE THE NATURAL OR RECONSTRUCTED EPIDERM, EQUIVALENT FROM SKIN OBTAINED |
WO2002038110A2 (en) | 2000-11-13 | 2002-05-16 | L'oreal | Use of carbohydrate for enhancing the skin barrier function |
US20050118283A1 (en) * | 2002-04-09 | 2005-06-02 | Calverley Ruth R. | Skincare compositions and methods |
EP1652530A1 (en) | 2003-07-14 | 2006-05-03 | Japan Science and Technology Agency | Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer |
US20070071710A1 (en) * | 2005-09-23 | 2007-03-29 | Chanel Parfums Beaute | Extract of vanilla planifolia |
WO2007034042A2 (en) | 2005-09-23 | 2007-03-29 | Chanel Parfums Beaute | Vanilla planifolia extract, method for obtaining same, and cosmetic or dermatological composition containing same |
US20090035236A1 (en) * | 2007-07-31 | 2009-02-05 | Maes Daniel H | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent |
WO2009077995A1 (en) * | 2007-12-18 | 2009-06-25 | L'oreal | Cosmetic use of acid ceramidase type proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6649362B2 (en) * | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
FR2777183B1 (en) * | 1998-04-10 | 2001-03-02 | Oreal | USE OF AT LEAST ONE HYDROXYSTILBENE IN A COMPOSITION FOR PROMOTING DEQUAMATION OF THE SKIN AND COMPOSITION COMPRISING SAME |
EP2155157A1 (en) * | 2007-06-11 | 2010-02-24 | Chanel Parfums Beauté | Cosmetic use of active agents for stimulating the expression of fn3k and/or fn3k rp to improve the skin's barrier function |
-
2010
- 2010-12-03 ES ES10787115.4T patent/ES2526540T3/en active Active
- 2010-12-03 JP JP2012542471A patent/JP5847090B2/en active Active
- 2010-12-03 EP EP10787115.4A patent/EP2510112B1/en active Active
- 2010-12-03 US US13/514,412 patent/US9228999B2/en active Active
- 2010-12-03 WO PCT/EP2010/068849 patent/WO2011069913A1/en active Application Filing
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2811556A1 (en) | 2000-07-11 | 2002-01-18 | Oreal | COMPOSITION COMPRISING A PRECURSOR OF CERAMIDES, USE TO ENHANCE THE NATURAL OR RECONSTRUCTED EPIDERM, EQUIVALENT FROM SKIN OBTAINED |
US20040018218A1 (en) * | 2000-07-11 | 2004-01-29 | Michel Philippe | Composition comprising a ceramide precursor for improving natural or reconstructed epidermis, resulting skin equivalent |
WO2002038110A2 (en) | 2000-11-13 | 2002-05-16 | L'oreal | Use of carbohydrate for enhancing the skin barrier function |
US20050118283A1 (en) * | 2002-04-09 | 2005-06-02 | Calverley Ruth R. | Skincare compositions and methods |
EP1652530A1 (en) | 2003-07-14 | 2006-05-03 | Japan Science and Technology Agency | Drug promoting ceramide transport, base sequence for producing the drug, method of measuring activity of promoting ceramide release and method of measuring activity of promoting intermembrane ceramide transfer |
US20080085859A1 (en) * | 2003-07-14 | 2008-04-10 | Japan Science And Technology Agency | Drug Promoting Ceramide Transport, Base Sequence for Producing the Drug, Method of Measuring Activity of Promoting Ceramide Release and Method of Measuring Activity of Promoting Intermembrane Ceramide Transfer |
US20070071710A1 (en) * | 2005-09-23 | 2007-03-29 | Chanel Parfums Beaute | Extract of vanilla planifolia |
WO2007034042A2 (en) | 2005-09-23 | 2007-03-29 | Chanel Parfums Beaute | Vanilla planifolia extract, method for obtaining same, and cosmetic or dermatological composition containing same |
US20090035236A1 (en) * | 2007-07-31 | 2009-02-05 | Maes Daniel H | Emulsion Cosmetic Compositions Containing Resveratrol Derivatives And An Oil Phase Structuring Agent |
WO2009077995A1 (en) * | 2007-12-18 | 2009-06-25 | L'oreal | Cosmetic use of acid ceramidase type proteins |
Non-Patent Citations (11)
Title |
---|
"International Cosmetic Ingredient Dictionary and Handbook", 2006, THE COSMETIC, TOILETRY AND FRAGRANCE ASSOCIATION |
BISSETT ET AL: "Common cosmeceuticals", CLINICS IN DERMATOLOGY, J.B. LIPPINCOTT, PHILADELPHIA, PA, US, vol. 27, no. 5, 1 September 2009 (2009-09-01), pages 435 - 445, XP026471172, ISSN: 0738-081X, [retrieved on 20090818], DOI: DOI:10.1016/J.CLINDERMATOL.2009.05.006 * |
CHARRUYER ALEXANDRA ET AL: "Decreased ceramide transport protein (CERT) function alters sphingomyelin production following UVB irradiation.", THE JOURNAL OF BIOLOGICAL CHEMISTRY 13 JUN 2008 LNKD- PUBMED:18411267, vol. 283, no. 24, 13 June 2008 (2008-06-13), pages 16682 - 16692, XP002622419, ISSN: 0021-9258 * |
CHARRUYER ET AL., J. BIOL. CHEM., vol. 283, pages 16682 - 16692 |
ELBADAWY H ET AL: "Expression of the START family of lipid trafficking proteins in HaCaT keratinocytes: evidence for a role for STARD5 in keratinocyte differentiation and cholesterol homeostasis", BRITISH JOURNAL OF DERMATOLOGY, vol. 162, no. 4, April 2010 (2010-04-01), & ANNUAL MEETING OF THE BRITISH-SOCIETY-FOR-INVESTIGATIVE-DERMATOLOGY; EDINBURGH, UK; APRIL 12 -14, 2010, pages 929, XP002622421 * |
HANADA ET AL., NATURE, vol. 426, pages 803 - 809 |
HANADA K ET AL: "CERT-mediated trafficking of ceramide", BIOCHIMICA AND BIOPHYSICA ACTA. MOLECULAR AND CELL BIOLOGY OFLIPIDS, ELSEVIER, AMSTERDAM, NL, vol. 1791, no. 7, 1 July 2009 (2009-07-01), pages 684 - 691, XP026174177, ISSN: 1388-1981, [retrieved on 20090122], DOI: DOI:10.1016/J.BBALIP.2009.01.006 * |
PFAFFL, MW, NUCLEIC ACIDS RES., vol. 29, no. 9, 2001, pages E45 |
RAO ET AL., PROC. NAT. ACAD. SCI. USA, vol. 104, pages 11364 - 11369 |
RAO RAGHAVENDRA PRALHADA ET AL: "Ceramide transfer protein function is essential for normal oxidative stress response and lifespan", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 104, no. 27, July 2007 (2007-07-01), pages 11364 - 11369, XP002622420, ISSN: 0027-8424 * |
Y. UCHIDA ET AL., JOURNAL OF LIPID RESEARCH, vol. 41, 2000, pages 2071 - 2082 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012156420A1 (en) * | 2011-05-17 | 2012-11-22 | Chanel Parfums Beaute | Large, hs6st2 or st8sia1 activators for preventing and/or attenuating skin ageing and/or hydrating skin |
US9745629B2 (en) | 2011-05-17 | 2017-08-29 | Chanel Parfums Beaute | In vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin, and/or for hydrating the skin |
WO2014009566A1 (en) * | 2012-07-13 | 2014-01-16 | Laboratoires Expanscience | Method for identifying molecular markers of children's skin |
FR2993282A1 (en) * | 2012-07-13 | 2014-01-17 | Expanscience Lab | METHOD FOR IDENTIFYING MOLECULAR MARKERS OF CHILD'S SKIN |
JP2015528699A (en) * | 2012-07-13 | 2015-10-01 | ラボラトワール エクスパンシアンス | Identification method of molecular markers in pediatric skin |
Also Published As
Publication number | Publication date |
---|---|
ES2526540T3 (en) | 2015-01-13 |
US9228999B2 (en) | 2016-01-05 |
EP2510112A1 (en) | 2012-10-17 |
EP2510112B1 (en) | 2014-11-26 |
US20120244545A1 (en) | 2012-09-27 |
JP2013512681A (en) | 2013-04-18 |
JP5847090B2 (en) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100028471A1 (en) | Cosmetic use of active agents that stimulate matriptase expression | |
US7642062B2 (en) | Compositions and methods of their use for improving the condition and appearance of skin | |
EP2953611B1 (en) | Use of a composition comprising avocado perseose in the protection of epidermal stem cells | |
EP2689767A1 (en) | Compositions and methods of their use for improving the condition and appearance of skin | |
US20100159045A1 (en) | Cosmetic use of active agents for stimulating the expression of fn3k and/or fn3k rp to improve the skin's barrier function | |
US20120237933A1 (en) | Method for screening active agents for treating at least one cutaneous sign of aging by determing the ability to stimulate fn3k and/or fn3kp expression | |
EP2618808B1 (en) | Cosmetic use of dermicidin and fragments thereof | |
JP6517328B2 (en) | SESTRIN activators for the prevention and / or alleviation of skin aging, and / or the moisturization and / or suppression of skin pigmentation | |
US9228999B2 (en) | Method for screening active agents that stimulate the expression of CERT to improve the skin's barrier function | |
JP7466721B2 (en) | Improves skin barrier function caused by stress | |
FR2902656A1 (en) | Active agent for cosmetic skin treatment, having e.g. protecting, repair promoting, moisturizing, antiaging and anti-wrinkle effects, comprises extract of Withania somnifera | |
CN115227774A (en) | Use of Phalaenopsis amabilis extract for preparing composition for inhibiting formation of saccharification final product | |
FR2905857A1 (en) | Cosmetic process, useful to care human skin, to hydrate and/or protect against dryness, comprises topical application of composition containing an extract of carob (Ceratonia siliqua) pulp on the skin | |
FR2965357A1 (en) | Use of at least one amino acid sequence encoded by a nucleic acid sequence or of nucleic acid sequence, as a biomarker of a state of aged skin and/or signs of aging, optionally associated with dry skin | |
US20120237941A1 (en) | Method for screening active agents that stimulate the expression of arnt2 to improve the skin's barrier function | |
FR2965358A1 (en) | Use of at least one amino acid sequence encoded by a nucleic acid sequence or of nucleic acid sequence, as a biomarker of a state of aged skin and/or signs of aging, optionally associated with dry skin | |
WO2014093053A1 (en) | Modulation of thymosin beta-4 in skin | |
FR3056910A1 (en) | USE BETA- (C8-C20) -ALKYLESTER OF (C1-C6) -ALKYL-D-GLUCOSIDE AS PROTECTIVE AGENT OF THE SKIN | |
US20140193529A1 (en) | Modulation of Thymosin Beta-4 in Skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10787115 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010787115 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012542471 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13514412 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |